A new tool for assessing the risk of developing knee osteoarthritis (OA) may be useful for knee OA education. A recent study found the online risk calculator, OA Risk C, was effective in helping patients better understand their personal risk of developing the disease. It may also motivate some patients to embrace exercise-related behavior changes…
Search results for: hospital
Abatacept Approved for Adult PsA
The FDA has approved abatacept to treat adults with active psoriatic arthritis. In clinical trials, the treatment has proved effective in both intravenous and subcutaneous forms…
What Rheumatologists Are Paid
A 2017 survey showed that rheumatologists’ pay has plateaued. And according to Anne Bass, MD, many cognitive fields, such as pediatrics and endocrinology, remain underpaid due to the current reimbursement structure…
Progress Made During HOD Annual Meeting
The AMA House of Delegates (HOD) met in Chicago for its annual meeting June 9–14. More than 530 HOD members were present, with several hundred AMA and association staff and guests. As I am sure you have noted from past issues of ACR@Work, the ACR is in its five-year membership review. The ACR must be…
Anti-CarP May Play Special Role in RA-Associated Mortality
Researchers may have established a relationship between a new RA autoantibody, anti-carbamylated protein (anti-CarP) antibodies, and increased mortality risk. The recent study showed that anti-CarP was the only autoantibody associated with mortality, specifically respiratory system cause of death…
Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…
U.S. Republicans Left Scrambling After Healthcare Bill Sinks Again
WASHINGTON (Reuters)—The collapse of Republicans’ push to repeal and replace Obamacare in the U.S. Senate set up a possible repeal-only vote and clouded the path forward for President Donald Trump’s other domestic policy goals, rattling financial markets on Tuesday. After two Republicans said they would not back the latest Obamacare rollback bill, Senate Majority Leader…
Drug Tapering: Studies Point to Success in Some Patients
Highlights from the 2017 EULAR Congress MADRID—Scores on the Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ) and C-reactive protein (CRP) levels were independent predictors of whether patients could be tapered successfully from a TNF inhibitor after having reached remission of their RA, according to findings presented in a session at the Annual European Congress of…
2 Biosimilars Make Their Way Toward the European Market
Two biosimilar treatments, Rixathon and Imraldi, are moving closer to market release in Europe for the treatment of rheumatic and other diseases…
Ethics Forum: Facebook Friend Request from Patient Raises Concern for Rheumatologist
Social media has revolutionized my practice. I stay current with Twitter content from other rheumatologists, patient organizations and medical journals. I am also an active member of the international Twitter-based rheumatology journal club, #RheumJC. Still, I was recently surprised when my patient’s name appeared in a friend request. This same patient was following me on…
- « Previous Page
- 1
- …
- 178
- 179
- 180
- 181
- 182
- …
- 323
- Next Page »